Edwards Launches SAPIAN 3 Ultra RESILIA Valve Following FDA Approval

Sep 12, 2022 | Industry Press Releases

IRVINE, Calif.,¬†Sept. 12, 2022¬†/PRNewswire/ — Edwards Lifesciences (NYSE: EW) today announced the launch of the SAPIEN 3 Ultra RESILIA valve, which incorporates Edwards’ breakthrough RESILIA tissue technology with the industry-leading SAPIEN 3 Ultra transcatheter aortic heart valve. The launch follows recent U.S. Food and Drug Administration (FDA) approval.